Trial reportMolecular medicine (Cambridge, Mass.)2012
T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.
Trial report in Molecular medicine (Cambridge, Mass.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis.The Laryngoscope · 2023Pooled it
- MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.Head & neck · 2019Trial
- Restricted Recruitment of NK Cells with Impaired Function Is Caused by HPV-Driven Immunosuppressive Microenvironment of Papillomas in Aggressive Juvenile-Onset Recurrent Respiratory Papillomatosis Patients.Journal of virology · 2022Article
- A review of the risk factors associated with juvenile-onset recurrent respiratory papillomatosis: genetic, immune and clinical aspects.World journal of pediatrics : WJP · 2022Review
- Article
- Oropharyngeal tumor cells induce COX-2 expression in peripheral blood monocytes by secretion of IL-1α.Frontiers in immunology · 2022Article
- HPV and Recurrent Respiratory Papillomatosis: A Brief Review.Life (Basel, Switzerland) · 2021Review
- How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis.The Laryngoscope · 2021Review
- Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.Clinical and experimental immunology · 2020Review
- Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis.PloS one · 2019Article
- Current and future management of recurrent respiratory papillomatosis.Laryngoscope investigative otolaryngology · 2018Review
- The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.The Laryngoscope · 2018Article
- Lymphocyte profile and cytokine mRNA expression in peripheral blood mononuclear cells of patients with recurrent respiratory papillomatosis suggest dysregulated cytokine mRNA response and impaired cytotoxic capacity.Immunity, inflammation and disease · 2017Article
- Poly(I:C) induces controlled release of IL-36γ from keratinocytes in the absence of cell death.Immunologic research · 2015Article
- Immune Dysregulation in Patients Persistently Infected with Human Papillomaviruses 6 and 11.Journal of clinical medicine · 2015Article
- Expression of human papillomavirus and prognosis of juvenile laryngeal papilloma.International journal of clinical and experimental medicine · 2015Article
- Immune therapy for human papillomaviruses-related cancers.World journal of clinical oncology · 2014Review
- Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.Molecular medicine (Cambridge, Mass.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Recurrent respiratory papillomatosis (RRP), characterized by the recurrent growth of benign tumors of the respiratory tract, is caused by infection with human papillomavirus (HPV), predominantly types 6 and 11. Surgical removal of these lesions can be required as frequently as every 3 to 4 wks to maintain a patent airway. There is no approved medical treatment for this disease. In this study, we have characterized the T(H)2-like chemokine profile (CCL17, CCL18, CCL20, CCL22) in patients with RRP and asked whether it was modulated in patients who had achieved significant clinical improvement. CCL17, CCL18 and CCL22 messenger RNAs (mRNAs) were increased in papillomas compared with clinically normal laryngeal epithelium of the RRP patients. Overall, CCL20 mRNA expression was not increased, but there was intense, selective CCL20 protein expression in the basal layer of the papillomas. Patients with RRP expressed more CCL17 (p = 0.003), CCL18 (p = 0.0003), and CCL22 (p = 0.007) in their plasma than controls. Plasma CCL18 decreased over time in three patients enrolled in a pilot clinical trial of celecoxib, and the decrease occurred in conjunction with clinical improvement. There was a significant correlation between sustained clinical remission in additional patients with RRP and reduced levels of CCL17 (p = 0.01), CCL22 (p = 0.002) and CCL18 (p = 0.05). Thus, the change in expression of these three plasma T(H)2-like chemokines may, with future studies, prove to serve as a useful biomarker for predicting disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.